-
Mashup Score: 37
PURPOSE Chemotherapy is established as primary treatment in patients with stage IV colorectal cancer and unresectable metastases. Data from nonrandomized clinical trials have fueled persistent uncertainty if primary tumor resection (PTR) before chemotherapy prolongs survival. We investigated the prognostic value of PTR in patients with newly diagnosed stage IV colon cancer who were not amenable to curative treatment. PATIENTS AND METHODS Patients enrolled in the multicenter, randomized SYNCHRONOUS and CCRe-IV trials were included in the analysis. Patients with colon cancer with synchronous unresectable metastases were randomly assigned at 100 sites in Austria, Germany, and Spain to undergo PTR or up-front chemotherapy (No PTR group). The chemotherapy regimen was left at discretion of the local team. Patients with tumor-related symptoms, inability to tolerate surgery and/or systemic chemotherapy, and history of another cancer were excluded. The primary end point was overall survival (OS
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4JAK2 wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy - 3 day(s) ago
TO THE EDITOR:
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Revolving doors: board memberships, hedge funds, and the FDA chiefs responsible for regulating industry - 3 day(s) ago
The US Food and Drug Administration says that it takes conflicts of interest seriously. But financial entanglements with the drug industry are common among its leaders. Peter Doshi reports At his public confirmation hearing in late 2021, Robert Califf, President Biden’s nominee to lead the US Food and Drug Administration (FDA), faced pointed questions about his financial relationships with industry. Bernie Sanders, the senator from Vermont, asked, “At a time when the American people are outraged by the high cost of prescription drugs, deeply disturbed about what happened with Purdue and Oxycontin, what kind of comfort can you give to the American people when you have been so closely tied to the pharmaceutical industry yourself?” He added, “How can the American people feel comfortable you’re going to stand up to this powerful special interest?” Califf responded: “Senator Sanders, I have a history of doing that. But I’d also point out that this administration has the most stringent ethic
Source: www.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6Neoadjuvant immunotherapy in patients with melanoma... let's get ready for ASCO-2024 plenary ! - 4 day(s) ago
A re-analysis of the SWOG S1801 trial (neoadjuvant pembrolizumab versus adjuvant only), and more…
Source: www.drugdevletter.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 37
In a pair of Special Reports, Gökbuget and colleagues present updated European Leukemia Net (ELN) consensus reports on (1) the diagnosis, prognostic factor
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31How I treat long-term survivors of childhood acute leukemia - 5 day(s) ago
Saultier and Michel provide guidance on the risk-stratification, diagnosis, and clinical management principles underpinning care for the ever-increasing nu
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31How I treat long-term survivors of childhood acute leukemia - 6 day(s) ago
Saultier and Michel provide guidance on the risk-stratification, diagnosis, and clinical management principles underpinning care for the ever-increasing nu
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11ADAMTS13 recovery in caplacizumab-treated TTP - 7 day(s) ago
In this issue of Blood, Mingot-Castellano et al, on behalf of the Spanish Apheresis Group and the Spanish Thrombotic Thrombocytopenic Purpura Registry, pre
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 33
PURPOSE Chemotherapy is established as primary treatment in patients with stage IV colorectal cancer and unresectable metastases. Data from nonrandomized clinical trials have fueled persistent uncertainty if primary tumor resection (PTR) before chemotherapy prolongs survival. We investigated the prognostic value of PTR in patients with newly diagnosed stage IV colon cancer who were not amenable to curative treatment. PATIENTS AND METHODS Patients enrolled in the multicenter, randomized SYNCHRONOUS and CCRe-IV trials were included in the analysis. Patients with colon cancer with synchronous unresectable metastases were randomly assigned at 100 sites in Austria, Germany, and Spain to undergo PTR or up-front chemotherapy (No PTR group). The chemotherapy regimen was left at discretion of the local team. Patients with tumor-related symptoms, inability to tolerate surgery and/or systemic chemotherapy, and history of another cancer were excluded. The primary end point was overall survival (OS
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
RT @ArndtVogel: Primary Tumor Resection Before Systemic Therapy in CRC & Unresectable Metastases @JCO_ASCO https://t.co/FCqc7D7cjZ 🔎SYNCHR…